Medicare drug coverage
Farxiga: 2027 Medicare Part D coverage
5,495 of 5,495 Part D plans (100%) list Farxiga on their 2027 formulary, the plan's list of covered drugs (up 42 points from 2026). 98% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).
License: a US government work, in the public domain (Public Domain Mark 1.0).
Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.
For pharmacies and agencies: check a whole drug list against 2027 formularies.
Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.
2027 compared with 2026
Farxiga is number 8 by total Medicare Part D spending in 2024 ($5.3 billion). Plans that list it most often put it on tier 3 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 3 RxNorm products for this name.
| Measure | 2026 | 2027 | Change |
|---|---|---|---|
| Part D plans in the file | 5,518 | 5,495 | -23 |
| Plans that list it | 3,174 (58%) | 5,495 (100%) | +42 points |
| Prior authorization (of plans that list it) | 0 (0%) | 961 (17%) | +17 points |
| Step therapy (of plans that list it) | 0 (0%) | 1,786 (33%) | +33 points |
| Quantity limit (of plans that list it) | 3,125 (98%) | 5,355 (97%) | -1 point |
| Any of the three (of plans that list it) | 3,125 (98%) | 5,361 (98%) | no change |
| Not listed or restricted (of all plans) | 5,469 (99%) | 5,361 (98%) | -1 point |
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
Every 2027 stand-alone drug plan
Each stand-alone Part D plan (PDP) with Farxiga's 2027 tier and limits. CMS files a PDP once per region, so one plan name can have several plan IDs; the row shows the tier and limits most of them use. Medicare Advantage drug plans are local: pick a state for its plan-by-plan table.
| Plan (PDP) | Plan IDs | 2027 tier | 2027 limits |
|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | 39 | Tier 3 | ST, QL |
| AARP Medicare Rx Saver from UHC (PDP) | 34 | Tier 3 | ST, QL |
| Blue Medicare Rx Enhanced (PDP) | 1 | Tier 3 | ST, QL |
| Blue Medicare Rx Standard (PDP) | 1 | Tier 3 | ST, QL |
| Blue MedicareRx Essentials (PDP) | 1 | Tier 3 | QL |
| Blue MedicareRx Plus (PDP) | 1 | Tier 3 | QL |
| Blue MedicareRx Premier (PDP) | 1 | Tier 3 | QL |
| Blue MedicareRx Value (PDP) | 1 | Tier 3 | QL |
| Blue MedicareRx Value Plus (PDP) | 1 | Tier 3 | QL |
| Blue Shield Rx Enhanced (PDP) | 1 | Tier 3 | ST, QL |
| Blue Shield Rx Plus (PDP) | 1 | Tier 3 | ST, QL |
| BlueMedicare Complete Rx (PDP) | 1 | Tier 3 | QL |
| BlueMedicare Premier Rx (PDP) | 2 | Tier 3 | QL |
| BlueMedicare Value Rx (PDP) | 1 | Tier 3 | QL |
| BlueRx Enhanced Plus (PDP) | 1 | Tier 3 | QL |
| BlueRx Essential (PDP) | 1 | Tier 3 | QL |
| HealthSpring Assurance Rx (PDP) | 35 | Tier 3 | ST, QL |
| HealthSpring Extra Rx (PDP) | 2 | Tier 3 | ST, QL |
| HealthSpring Extra RX (PDP) | 3 | Tier 3 | ST, QL |
| Horizon Medicare Blue Rx Enhanced (PDP) | 1 | Tier 3 | QL |
| Horizon Medicare Blue Rx Standard (PDP) | 1 | Tier 3 | QL |
| Humana Basic Rx Plan (PDP) | 34 | Tier 3 | PA, QL |
| Humana Premier Rx Plan (PDP) | 34 | Tier 3 | PA, QL |
| Humana Value Rx Plan (PDP) | 34 | Tier 3 | PA, QL |
| MedicareBlue Rx Standard (PDP) | 1 | Tier 3 | QL |
| Prescription Blue Premium (PDP) | 1 | Tier 3 | ST, QL |
| Prescription Blue Select (PDP) | 1 | Tier 3 | ST, QL |
| SilverScript Choice (PDP) | 20 | Tier 3 | QL |
| Wellcare Classic (PDP) | 34 | Tier 2 | ST, QL |
| Wellcare Value Script (PDP) | 34 | Tier 2 | ST, QL |
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Formulary tier
| Tier | 2026 plans | 2027 plans |
|---|---|---|
| Tier 1 | 50 (2%) | 123 (2%) |
| Tier 2 | 38 (1%) | 305 (6%) |
| Tier 3 | 3,059 (96%) | 5,038 (92%) |
| Tier 4 | 0 (0%) | 13 (<1%) |
| Tier 5 | 9 (<1%) | 8 (<1%) |
| Tier 6 | 18 (1%) | 8 (<1%) |
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
Plan by plan, 2026 to 2027
4,380 plan IDs are in both files. 1,095 of them (25%) added prior authorization, step therapy, or a quantity limit for Farxiga, and 0 stopped listing it.
| Plan by plan | Plans |
|---|---|
| Same plan ID in both years | 4,380 |
| Listed it in 2026, not in 2027 | 0 (0%) |
| Listed it in 2027, not in 2026 | 1,829 (42%) |
| Moved it to a higher tier | 19 (<1%) |
| Added prior authorization | 799 (18%) |
| Added step therapy | 296 (7%) |
| Added a quantity limit | 19 (<1%) |
| Added at least one of the three | 1,095 (25%) |
| Removed at least one of the three | 0 (0%) |
| Plan IDs new in 2027 | 1,115 |
| 2026 plan IDs not in the 2027 file | 1,138 |
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
States from most to least restrictive
Share of 2027 Part D plans offered in each state that leave Farxiga off the formulary or list it with prior authorization, step therapy, or a quantity limit. 39 states tie for the highest share, 100%; Maryland ranks last at 80%. States at the same share are ordered by the prior authorization or step therapy share; states equal on both shares share a rank, marked Tied.
| Rank | State | 2027 plans | Not listed or restricted | Prior auth or step therapy | Change from 2026 |
|---|---|---|---|---|---|
| 1 | Montana | 27 | 100% | 96% | no change |
| 2 | Wyoming | 13 | 100% | 92% | no change |
| 3 | Alaska | 9 | 100% | 89% | no change |
| 4 | Vermont | 14 | 100% | 86% | no change |
| 5 | North Dakota | 26 | 100% | 85% | no change |
| 6 | Idaho | 45 | 100% | 84% | no change |
| 7 | New Hampshire | 25 | 100% | 76% | no change |
| 8 | South Dakota | 30 | 100% | 73% | no change |
| 9 | New Mexico | 68 | 100% | 72% | no change |
| Tied 10 | South Carolina | 91 | 100% | 70% | no change |
| Tied 10 | Delaware | 43 | 100% | 70% | no change |
| 12 | Mississippi | 105 | 100% | 68% | no change |
| 13 | Michigan | 183 | 100% | 67% | no change |
| 14 | Maine | 52 | 100% | 65% | no change |
| 15 | Kentucky | 123 | 100% | 63% | no change |
| Tied 16 | Utah | 53 | 100% | 62% | no change |
| Tied 16 | Oklahoma | 81 | 100% | 62% | no change |
| Tied 18 | Louisiana | 126 | 100% | 59% | no change |
| Tied 18 | Rhode Island | 29 | 100% | 59% | no change |
| Tied 20 | West Virginia | 70 | 100% | 57% | no change |
| Tied 20 | Arkansas | 86 | 100% | 57% | no change |
| Tied 20 | Nebraska | 51 | 100% | 57% | no change |
| 23 | Pennsylvania | 324 | 100% | 56% | no change |
| Tied 24 | New Jersey | 74 | 100% | 55% | no change |
| Tied 24 | North Carolina | 177 | 100% | 55% | no change |
| Tied 26 | Texas | 412 | 100% | 52% | no change |
| Tied 26 | Iowa | 64 | 100% | 52% | no change |
| Tied 28 | Illinois | 133 | 100% | 51% | no change |
| Tied 28 | Massachusetts | 92 | 100% | 51% | +23 points |
| Tied 28 | Minnesota | 63 | 100% | 51% | no change |
| Tied 31 | Arizona | 148 | 100% | 49% | no change |
| Tied 31 | Alabama | 115 | 100% | 49% | no change |
| Tied 31 | Ohio | 173 | 100% | 49% | no change |
| 34 | Kansas | 84 | 100% | 48% | no change |
| 35 | Missouri | 171 | 100% | 47% | no change |
| 36 | Indiana | 140 | 100% | 45% | no change |
| 37 | Connecticut | 54 | 100% | 43% | +4 points |
| 38 | Florida | 549 | 100% | 41% | no change |
| 39 | Tennessee | 157 | 100% | 40% | no change |
| 40 | Wisconsin | 97 | 99% | 66% | no change |
| 41 | Nevada | 100 | 97% | 50% | -3 points |
| 42 | Virginia | 145 | 96% | 62% | -4 points |
| 43 | Oregon | 92 | 96% | 39% | -4 points |
| 44 | Georgia | 151 | 95% | 63% | -5 points |
| 45 | Colorado | 106 | 90% | 48% | -10 points |
| 46 | New York | 215 | 90% | 33% | +1 point |
| 47 | California | 397 | 88% | 45% | -12 points |
| 48 | Hawaii | 50 | 88% | 40% | -12 points |
| 49 | District of Columbia | 21 | 86% | 67% | -14 points |
| 50 | Washington | 114 | 86% | 48% | -14 points |
| 51 | Maryland | 49 | 80% | 39% | -20 points |
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
By parent organization
164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Farxiga off or restrict it.
| Parent organization | 2027 plans ↑ | List it | Restrict it (of listing) | Not listed or restricted | Change from 2026 | Plans that added a restriction |
|---|---|---|---|---|---|---|
| CoxHealth | 3 | 100% | 100% | 100% | no change | 0 |
| First Sacramento Capital Funding LLC | 3 | 100% | 100% | 100% | no change | 0 |
| Imperial Health Plan of California | 3 | 100% | 100% | 100% | no change | 0 |
| Liberty Healthcare Insurance | 3 | 100% | 100% | 100% | no change | 0 |
| Marquis Companies I, Inc. | 3 | 100% | 100% | 100% | no change | 0 |
| McLaren Health Care Corporation | 3 | 100% | 100% | 100% | no change | 0 |
| MedCare Partners Holding, LLC | 3 | 100% | 100% | 100% | new in 2027 | 0 |
| Mercy Care | 3 | 100% | 100% | 100% | no change | 0 |
| New York City Health and Hospitals Corporation | 3 | 100% | 100% | 100% | no change | 0 |
| Presbyterian Healthcare Services | 3 | 100% | 100% | 100% | no change | 0 |
| SIHO Holding, Inc. | 3 | 100% | 100% | 100% | no change | 0 |
| St. Luke's Health System, Inc. | 3 | 100% | 100% | 100% | new in 2027 | 0 |
| VISITING NURSE ASSOCIATION OF CENTRAL NEW YORK | 3 | 100% | 100% | 100% | no change | 0 |
| Village Care of New York, Inc. | 3 | 100% | 100% | 100% | no change | 0 |
| Visiting Nurse Service of New York | 3 | 100% | 100% | 100% | no change | 0 |
| Chapters CareNu Inc | 4 | 100% | 100% | 100% | no change | 0 |
| Chinese Hospital Association | 4 | 100% | 100% | 100% | no change | 0 |
| El Paso County Hospital District | 4 | 100% | 100% | 100% | no change | 0 |
| Elderplan, Inc. | 4 | 100% | 100% | 100% | no change | 0 |
| Horizon Mutual Holdings, Inc | 4 | 100% | 100% | 100% | no change | 0 |
| LMC Family Holdings, LLC | 4 | 100% | 100% | 100% | no change | 0 |
| Montage Health | 4 | 100% | 100% | 100% | no change | 0 |
| St Francis Health System & St John Health System | 4 | 100% | 100% | 100% | no change | 0 |
| Blue Cross & Blue Shield of Rhode Island | 5 | 100% | 100% | 100% | no change | 0 |
| BlueCross BlueShield of Alabama | 5 | 100% | 100% | 100% | no change | 0 |
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Other Dapagliflozin Propanediol products
Near it by Part D spending
About this data
A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.
A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page